Immuno-related adverse events from check-point inhibitors during immune-therapy for cancer. Imaging findings

2018 ◽  
Vol 92 ◽  
pp. S22
Author(s):  
F. Sandomenico ◽  
G. De rosa ◽  
S. Pizza ◽  
O. Catalano ◽  
S. Setola ◽  
...  
Keyword(s):  
Adverse Events ◽  
Cancer Imaging ◽  
Immune Therapy ◽  
Check Point ◽  
Imaging Findings ◽  
Check Point Inhibitors

scholarly journals Cutaneous Events Associated with Immunotherapy of Melanoma: A Review

2021 ◽  
Vol 10 (14) ◽  
pp. 3047
Author(s):  
Lorenza Burzi ◽  
Aurora Maria Alessandrini ◽  
Pietro Quaglino ◽  
Bianca Maria Piraccini ◽  
Emi Dika ◽  
...  
Keyword(s):  
Adverse Events ◽  
Checkpoint Inhibitors ◽  
Stage Iii ◽  
Check Point ◽  
Check Point Inhibitors

Immunotherapy with checkpoint inhibitors significantly improves the outcome for stage III and IV melanoma. Cutaneous adverse events during treatment are often reported. We herein aim to review the principal pigmentation changes induced by immune check-point inhibitors: the appearance of vitiligo, the Sutton phenomenon, melanosis and hair and nail toxicities.

Abstract 5631: Leukaemia and lymphoma patient-derived xenografts (PDX) engraft on humanized mice and respond to immune therapy with check point inhibitors

2020 ◽  
Author(s):  
Maria Stecklum ◽  
Annika Wulf-Goldenberg ◽  
Antje Siegert ◽  
Bernadette Brzezicha ◽  
Anja Sterner-Kock ◽  
...  
Keyword(s):  
Immune Therapy ◽  
Humanized Mice ◽  
Check Point ◽  
Lymphoma Patient ◽  
Check Point Inhibitors

Clinical outcomes of patients on check point inhibitor therapy who receive routine vaccinations.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e14597-e14597 ◽  
Author(s):  
Erin Lynn Schenk
Keyword(s):  
Adverse Events ◽  
Clinical Outcomes ◽  
Median Survival ◽  
Routine Vaccination ◽  
Check Point ◽  
Similar Frequency ◽  
Advanced Malignancies ◽  
Check Point Inhibitors ◽  
Single Vaccination ◽  
Grade 3

e14597 Background: Routine vaccination reduces preventable illness and infection in cancer patients even while undergoing therapy. Increasingly, patients with advanced malignancies receive check point inhibitors (CPI) and, with tumor response, can remain on therapy for extended periods of time. These agents promote tumor clearance by impeding a normal route of immune regulation which can result in autoimmunity. To the best of our knowledge, clinical outcomes for patients on CPI therapy who receive routine vaccinations have not been studied. Methods: The medical records of patients who received CPI therapy at Mayo Clinic in Rochester, Minnesota from March 25, 2011 to August 25, 2015 were reviewed for type and date of immunizations, CPI duration, adverse events (AE) at least possibly related to therapy, and survival from start of CPI. Patients who received > 1 dose of pembrolizumab or nivolumab were included in analysis. Patients were excluded if no follow up was done at our institution. Results: One hundred and eight patients were included in the analysis. Most patients received CPI therapy for metastatic melanoma (n = 71) or non-small cell lung cancer (n = 23). A total of 53 routine vaccinations were administered to 30 patients while on CPI therapy. Eighteen patients received a single vaccination. Annual influenza vaccination was most frequently administered (n = 38) followed by pneumococcal vaccines (n = 9). AEs were reported in 17/30 vaccinated patients and in 22/78 non-vaccinated patients (p = 0.004). In the vaccinated cohort, 11 patients experienced AEs after immunization and was not significantly different from the non-vaccinated patients (p = 0.265). For both cohorts, thyroid, rash, and pneumonitis were the most common AEs. Grade 3 AEs occurred with similar frequency between the 2 groups. Patients in the vaccinated cohort received more cycles of therapy (median 20.5 vs 6 cycles, p < 0.001). Median survival of patients who were not vaccinated was 503 days and median survival was not reached in the vaccinated group (p = 0.005). Conclusions: Routine vaccination of patients receiving CPI therapy did not significantly increase number or severity of adverse events. Routine vaccination did not reduce patient benefit from CPIs.

scholarly journals Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment

2020 ◽  
Vol 10 (3) ◽  
pp. 111-117
Author(s):  
A. M. Mudunov ◽  
A. V. Ignatova ◽  
A. S. Morozova ◽  
S. O. Podvyaznikov ◽  
Yu. V. Alymov
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Immune Therapy ◽  
Check Point ◽  
Platinum Based Chemotherapy ◽  
Study Results ◽  
Severe Adverse Events

Head and neck squamous cell carcinoma (HNSCC) is the most common cancer among head and neck malignancies and causes of cancer death. More than 50 % of patiens have relapses within first 3 years after treatment, with median survival less than 6 months. Cetuximab is the first targeted agent for HNSCC, is considered as alternative regiment in case of intolerance to platinum-based chemotherapy, and also can activate an antigenspecific T-cell immunity in head and neck cancer patients. Nivolumab is a check-point inhibitor, that improves overall survival of patients with advanced recurrent/metastatic HNSCC, due to the CheckMate-141 study results. The results of phase II study сoncurrent cetuximab and nivolumab in patients with recurrent and/or metastatic HNSCC showed a benefit for patients without prior check-point inhibitor exposure and overall well tolerated. Thus, we have 6 cases of HNSCC, treated with combination of nivolumab and cetuximab, resulted in durable (12 months) partial response or stabilization without severe adverse events. In our study, all 6 patients had prior check-point inhibitor exposure with nivolumab. Cetuximab was added to a treatment protocol after evidence-based progression during check-point inhibitor therapy. We demonstrate a case report of recurrent locally advanced HNSCC, treated with combination of nivolumab and cetuximab and resulted in stabilization. Only 1 patient had a progression after concurrent targeted and immune-therapy with nivolumab and cetuximab. New combination was well tolerated without severe adverse events. To our opinion, first results are challenging and we believe in great perspectives of comprehensive molecular profiling and combination of targeted and immune-therapy for better results.

scholarly journals Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Wanting Hou ◽  
Xiaohan Zhou ◽  
Cheng Yi ◽  
Hong Zhu
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Check Point ◽  
Small Cell Lung ◽  
Immune Microenvironment ◽  
Malignant Solid Tumor ◽  
Check Point Inhibitors

Small cell lung cancer (SCLC) is a malignant solid tumor. In recent years, although immune check point inhibitors (ICIs) have achieved important advances in the treatment of SCLC, immune-related adverse events (irAEs) have occurred at the same time during the therapeutic period. Some irAEs lead to dose reduction or treatment rejection. The immune microenvironment of SCLC is complicated, therefore, understanding irAEs associated with ICIs is of great importance and necessity for the clinical management of SCLC. However, the lack of comprehensive understanding of irAEs in patients with SCLC remains remarkable. This review aims to provide an up-to-date overview of ICIs and their associated irAEs in patients with SCLC based on present clinical data.

Immune Checkpoint Inhibitor (ICPI) induced Nephrotoxicity – An Insight.

JMS SKIMS ◽  
2020 ◽  
Vol 23 (3) ◽  
Author(s):  
Mohmad Hussian Mir ◽  
Tariq Ahmad Bhat ◽  
Khalid Parvez Sofi ◽  
Imtiyaz Ahmad Wani ◽  
Muzafar Maqsood Wani
Keyword(s):  
Acute Kidney Injury ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Kidney Injury ◽  
Check Point ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
New Class ◽  
Transplant Patients ◽  
Check Point Inhibitors

Immune check point inhibitors (ICPIs) are a new class of anti-neoplastic agents being increasingly used by oncologists to treat various malignancies. These drugs have been associated with varied side effects and have a nephrotoxic potential. Many cases of ICPI induced acute kidney injury are increasingly being reported. Their use in CKD patients on dialysis as well as in kidney transplant recipients is associated with various challenges. This review discusses the use of ICPIs in CKD, dialysis and renal transplant patients and their nephrotoxic potential  

Sign in / Sign up

Export Citation Format

Share Document